Sign in
Not yet recruitingPhase 4

Mepolizumab with smaller or larger sinus surgery for chronic rhinosinusitis with nasal polyps

Compares mepolizumab with simple polyp removal or wider sinus surgery in adults with nasal polyps.

Key facts

Who runs it
Eye & ENT Hospital of Fudan University
Where
China17 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP
Status
Not yet recruiting
Phase
Phase 4
People taking part
360 people, planned
Started
8 Oct 2025
Expected to end
10 Oct 2031
Type of study
Interventional, 3 groups
Treatments tested
  • Mepolizumab
  • Simple Polypectomy
  • Extended Endoscopic Sinus Surgery
Record updated
1 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic rhinosinusitis with nasal polyps (long-lasting sinus swelling with growths in the nose). Everyone gets the anti-IL-5 drug mepolizumab, alone, with simple polyp removal, or with extended sinus surgery.

Age
18 Years to 75 Years
Sex
All
Disease stage
Polyps in both sides of the nose seen by endoscopy (a camera exam), with a polyp score of ≥4 in total (≥2 per side). Blocked nose for >3 months, with a blockage score of ≥2 and/or a loss-of-smell score of ≥2.
Earlier treatment
Standard medicine did not help after 4 weeks, including nose steroid sprays for >4 weeks. People who had sinus surgery for this disease before cannot join. No steroid tablets within 1 month.
Biomarker or test result
Signs of type 2 inflammation: eosinophils (a type of white blood cell) in polyp tissue >55/HPF or >27% of inflammatory cells, or blood eosinophils ≥6.9% (without asthma) or ≥3.7% (with asthma).

Main reasons for not taking part

  • Cystic fibrosis, Young's syndrome, Kartagener syndrome, antrochoanal polyp or rhinitis medicamentosa
  • HIV infection, or a parasite infection within 6 months
  • Allergy to monoclonal antibodies or anti-IL-5 drugs
  • Pregnancy, planning a pregnancy, or breastfeeding
  • Uncontrolled body-wide diseases, or a strongly bent nasal wall (septum)

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Endoscopy shows bilateral nasal polyps, with bilateral NPS ≥4 (≥2 per side)
  • Nasal obstruction symptoms >3 months, nasal obstruction score ≥2 (total 3 points) and/or hyposmia ≥2 (maximum 3 points)
  • Evidence of type 2 inflammation: Nasal polyp tissue Eos >55/HPF or >27% of inflammatory cells; or Peripheral blood Eos ≥6.9% (without asthma) or ≥3.7% (with asthma) Note: Meet any 2 of the above 3 criteria
  • Failure after 4 weeks of standard medical therapy including: Intranasal corticosteroids >4 weeks; Other agents (oral steroids, macrolides, antihistamines, leukotriene receptor antagonists, decongestants, antibiotics) permitted as needed

Who cannot take part

  • History of hypersensitivity to investigational drugs (except aspirin intolerance)
  • Oral steroid therapy within 1 month
  • Have a history of previous sinus surgery for CRSwNP
  • Cystic fibrosis, Young's syndrome, Kartagener syndrome, antrochoanal polyp, or rhinitis medicamentosa
  • Acute upper respiratory infection within 2 weeks
  • HIV infection
  • Parasitic infection within 6 months
  • Hypersensitivity to monoclonal antibodies or anti-IL-5 agents
  • Uncontrolled systemic diseases
  • Asthma exacerbation within 1 month
  • Pregnancy planning, current pregnancy, or lactation
  • Significant septal deviation affecting unilateral ventilation (mild deviation allowed)
  • Investigator judgment of unsuitability for cohort study

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study compares two surgical approaches combined with anti-IL-5 therapy in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Patients will be randomly assigned to one of the three groups: (1) anti-IL-5 alone, (2) anti-IL-5 with simple polyp removal, or (3) anti-IL-5 with extended sinus surgery. The aim of this study is to see if a less invasive surgery (simple polyp removal) with anti-IL-5 works as well as more extensive surgery with anti-IL-5. Participants will be followed for 1 to 3 years.

The 3 groups in the trial

  • Anti-IL-5 MonotherapyTreatment being tested

    Mepolizumab 100mg subcutaneously every 4 weeks for 24 weeks

    Treatment: Mepolizumab

  • Anti-IL-5 + Simple PolypectomyTreatment being tested

    Combined therapy: A 100 mg dose of mepolizumab is initiated subcutaneously 2 weeks after simple polypectomy. Mepolizumab will be administered subcutaneously every 4 weeks for 24 weeks.

    Treatment: Mepolizumab and Simple Polypectomy

  • Anti-IL-5 + Extended Endoscopic Sinus SurgeryTreatment being tested

    Combined therapy: A 100 mg dose of mepolizumab is initiated subcutaneously 2 weeks after Extended Endoscopic Sinus Surgery. Mepolizumab will be administered subcutaneously every 4 weeks for 24 weeks.

    Treatment: Mepolizumab and Extended Endoscopic Sinus Surgery

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Anti-IL-5 Therapy Combined With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery in Patients With CRSwNP: A Multicenter Randomized Controlled Trial
Plain-language title
Mepolizumab with smaller or larger sinus surgery for chronic rhinosinusitis with nasal polypsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07200336, who can take part
Record updated
1 October 2025